Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kempf

Showing results (291-300 of 415) with videos related to

Pageof 42
Sort By:
Lancet (London, England)|December 24, 2014
Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive careTimo Wolf, Gerrit Kann, Stephan Becker, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 2008
Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerasePamela L Donner, Qinghua Xie, John K Pratt, et al.
FEMS Microbiology Reviews|February 17, 2022
Contemporary diagnostics for medically relevant fastidious microorganisms belonging to the genera Anaplasma,Bartonella,Coxiella,OrientiaandRickettsiaDiana J Vaca, Gerhard Dobler, Silke F Fischer, et al.
Microorganisms|November 25, 2023
Analysis of Mould Exposure of Immunosuppressed Patients at a German University HospitalDanuta Puhlmann, Dominic Bergmann, Silke Besier, et al.
Scientific Reports|November 27, 2025
Dynamics of postnatal upper airway bacteria colonization in preterm infants <1000g and bronchopulmonary dysplasiaTina Frodermann, Ulrich Rochwalsky, Ariane Selting, et al.
FEBS Letters|August 23, 1993
Pseudo-symmetrical difluoroketones. Highly potent and specific inhibitors of HIV-1 proteaseH L Sham, D A Betebenner, N Wideburg, et al.
Plos One|July 21, 2010
Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogensNadine Werth, Christiane Beerlage, Christian Rosenberger, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitorsDale J Kempf, Jeffrey F Waring, David C Morfitt, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 1994
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral proteaseA H Kaplan, S F Michael, R S Wehbie, et al.
AIDS (London, England)|April 16, 1998
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadirD J Kempf, R A Rode, Y Xu, et al.
Pageof 42

Showing results (291-300 of 415) with videos related to

Sort By:
Pageof 42
Lancet (London, England)|December 24, 2014
Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive careTimo Wolf, Gerrit Kann, Stephan Becker, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 2008
Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerasePamela L Donner, Qinghua Xie, John K Pratt, et al.
FEMS Microbiology Reviews|February 17, 2022
Contemporary diagnostics for medically relevant fastidious microorganisms belonging to the genera Anaplasma,Bartonella,Coxiella,OrientiaandRickettsiaDiana J Vaca, Gerhard Dobler, Silke F Fischer, et al.
Microorganisms|November 25, 2023
Analysis of Mould Exposure of Immunosuppressed Patients at a German University HospitalDanuta Puhlmann, Dominic Bergmann, Silke Besier, et al.
Scientific Reports|November 27, 2025
Dynamics of postnatal upper airway bacteria colonization in preterm infants <1000g and bronchopulmonary dysplasiaTina Frodermann, Ulrich Rochwalsky, Ariane Selting, et al.
FEBS Letters|August 23, 1993
Pseudo-symmetrical difluoroketones. Highly potent and specific inhibitors of HIV-1 proteaseH L Sham, D A Betebenner, N Wideburg, et al.
Plos One|July 21, 2010
Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogensNadine Werth, Christiane Beerlage, Christian Rosenberger, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitorsDale J Kempf, Jeffrey F Waring, David C Morfitt, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 1994
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral proteaseA H Kaplan, S F Michael, R S Wehbie, et al.
AIDS (London, England)|April 16, 1998
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadirD J Kempf, R A Rode, Y Xu, et al.
Pageof 42